De Baere Thierry, de Mendonça Ricardo, Claeys Geert, Verschraegen Gerda, Mijs Wouter, Verhelst Rita, Rottiers Sylvianne, Van Simaey Leen, De Ganck Catharine, Vaneechoutte Mario
Department Clinical Chemistry, Microbiology & Immunology, Ghent University Hospital, Ghent, Belgium.
BMC Microbiol. 2002 Mar 1;2:4. doi: 10.1186/1471-2180-2-4.
The development of DNA amplification for the direct detection of M. tuberculosis from clinical samples has been a major goal of clinical microbiology during the last ten years. However, the limited sensitivity of most DNA amplification techniques restricts their use to smear positive samples. On the other hand, the development of automated liquid culture has increased the speed and sensitivity of cultivation of mycobacteria. We have opted to combine automated culture with rapid genotypic identification (ARDRA: amplified rDNA restriction analysis) for the detection resp. identification of all mycobacterial species at once, instead of attempting direct PCR based detection from clinical samples of M. tuberculosis only.
During 1998-2000 a total of approx. 3500 clinical samples was screened for the presence of M. tuberculosis. Of the 151 culture positive samples, 61 were M. tuberculosis culture positive. Of the 30 smear positive samples, 26 were M. tuberculosis positive. All but three of these 151 mycobacterial isolates could be identified with ARDRA within on average 36 hours. The three isolates that could not be identified belonged to rare species not yet included in our ARDRA fingerprint library or were isolates with an aberrant pattern.
In our hands, automated culture in combination with ARDRA provides with accurate, practically applicable, wide range identification of mycobacterial species. The existing identification library covers most species, and can be easily updated when new species are studied or described. The drawback is that ARDRA is culture-dependent, since automated culture of M. tuberculosis takes on average 16.7 days (range 6 to 29 days). However, culture is needed after all to assess the antibiotic susceptibility of the strains.
在过去十年中,开发用于直接从临床样本中检测结核分枝杆菌的DNA扩增技术一直是临床微生物学的主要目标。然而,大多数DNA扩增技术的灵敏度有限,限制了它们仅用于涂片阳性样本。另一方面,自动化液体培养的发展提高了分枝杆菌培养的速度和灵敏度。我们选择将自动化培养与快速基因型鉴定(ARDRA:扩增rDNA限制性分析)相结合,用于同时检测和鉴定所有分枝杆菌物种,而不是仅尝试从结核分枝杆菌的临床样本中进行基于直接PCR的检测。
在1998年至2000年期间,共对约3500份临床样本进行了结核分枝杆菌检测。在151份培养阳性样本中,61份为结核分枝杆菌培养阳性。在30份涂片阳性样本中,26份为结核分枝杆菌阳性。这151株分枝杆菌分离株中,除了3株外,其余均可在平均36小时内通过ARDRA鉴定。无法鉴定的3株分离株属于我们的ARDRA指纹库中尚未包含的稀有物种,或者是具有异常模式的分离株。
在我们的研究中,自动化培养与ARDRA相结合能够准确、实际可行且广泛地鉴定分枝杆菌物种。现有的鉴定文库涵盖了大多数物种,并且在研究或描述新物种时可以轻松更新。缺点是ARDRA依赖于培养,因为结核分枝杆菌的自动化培养平均需要16.7天(范围为6至29天)。然而,毕竟还是需要培养来评估菌株的抗生素敏感性。